UBS Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

UBS Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,500	Closed	-$4.18M	–	10436
2025 Q4	$4.18M	Hold	10,500	–	–	﹤0.01%	4205
2025 Q3	$4.79M	Hold	10,500	–	–	﹤0.01%	4085
2025 Q2	$3.42M	Buy	+10,500	New	+$2.91M	﹤0.01%	4267
2024 Q3	–	Sell	-24,900	Closed	-$6.05M	–	9462
2024 Q2	$6.05M	Sell	24,900 -2,600	-9%	-$410K	﹤0.01%	2670
2024 Q1	$4.11M	Buy	27,500 +13,000	+90%	+$2.17M	﹤0.01%	3181
2023 Q4	$2.78M	Buy	14,500 +9,700	+202%	+$1.65M	﹤0.01%	3466
2023 Q3	$850K	Buy	+4,800	New	+$916K	﹤0.01%	4228
2017 Q4	–	Sell	-45,200	Closed	-$5.31M	–	7819
2017 Q3	$5.31M	Buy	+45,200	New	+$3.86M	﹤0.01%	2145
2015 Q1	–	Sell	-100	Closed	-$10K	–	8745
2014 Q4	$10K	Buy	+100	New	+$9.27K	﹤0.01%	8366

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group's ALNY Position: Q1 2026 in Review

UBS Group reduced its Alnylam Pharmaceuticals (ALNY) stake by 44% in Q1 2026, selling an estimated $125M and leaving 458,870 shares worth $152M. The position accounts for 0.02% of the portfolio, ranked #763.

UBS Group first reported a position in ALNY in Q4 2014 and has held it in 46 quarters since. The position peaked at $328M in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

UBS Group held 458,870 shares of Alnylam Pharmaceuticals worth $152M as of Q1 2026.
UBS Group sold 366,970 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $125M.
Alnylam Pharmaceuticals made up 0.02% of UBS Group's portfolio in Q1 2026, its #763 holding.
UBS Group first reported a position in Alnylam Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
UBS Group's Alnylam Pharmaceuticals position peaked at $328M in Q4 2025.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.